Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1642 1644 1645 1651
This examiner grants 64% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18283196 | MATERIALS AND METHODS FOR TREATING CANCER | Final Rejection | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH |
| 17209160 | MATERIALS AND METHODS FOR TREATING CANCER | Non-Final OA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH |
| 18274069 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING DISEASE ASSOCIATED WITH AVB8 INTEGRIN | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18517417 | ARTIFICIAL PROTEIN TO RESTORE SYNAPTIC FUNCTION | Non-Final OA | PRESIDENT AND FELLOWS OF HARVARD COLLEGE |
| 18284725 | METHODS FOR DOSING AND TREATMENT WITH A COMBINATION OF A CHECKPOINT INHIBITOR THERAPY AND A CAR T CELL THERAPY | Non-Final OA | Juno Therapeutics, Inc. |
| 18038185 | HER2 TARGETING AGENT | Non-Final OA | TOHOKU UNIVERSITY |
| 18007008 | HUMANIZED ANTIBODY SPECIFIC TO BACILLUS ANTHRACIS PROTECTIVE ANTIGEN AND PREPARATION METHOD THEREOF | Non-Final OA | AGENCY FOR DEFENSE DEVELOPMENT |
| 18276710 | METHODS FOR DETECTING NEUROFILAMENT LIGHT CHAIN IN PLASMA AND CEREBROSPINAL FLUID | Non-Final OA | Washington University |
| 18681284 | NUCLEIC ACID STRUCTURE UTILIZING SNARE | Non-Final OA | Kao Corporation |
| 18565628 | THERAPEUTIC USE OF COMBINATION INCLUDING TRIPLE AGONIST HAVING ACTIVITIES TO ALL OF GLUCAGON, GLP-1, AND GIP RECEPTORS | Non-Final OA | HANMI PHARM. CO., LTD. |
| 17586067 | METHODS OF USE FOR CAR T CELLS | Non-Final OA | Seattle Children's Hospital (dba Seattle Children's Research Institute) |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy